QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gt-biopharma-q2-eps-217-down-from-149-yoy

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(2.17) per share. This is a 45.64 percent decrease over losses of $(1....

 gt-biopharma-announces-fda-clearance-for-gtb-3650-ind-application-phase-1-trial-to-begin-in-h2-2024-with-initial-data-expected-in-h1-2025

GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission ...

 whats-going-on-with-gt-biopharma-stock-tuesday

GT Biopharma entered into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common ...

 gt-biopharma-shares-resume-trade
GT Biopharma Shares Resume Trade
05/21/2024 13:39:14

 whats-going-on-with-gt-biopharma-stock

GT Biopharma shares are moving on heavy trading volume despite a lack of company-specific news. The stock is one of the top tre...

 gt-biopharma-shares-resume-trade
GT Biopharma Shares Resume Trade
05/20/2024 13:53:48

 gt-biopharma-q1-eps-164-beats-270-estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(1.64) per share which beat the analyst consensus estimate of $(2.70) ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION